

Special Issue

Novel Drugs for Treating Gynecologic Cancers

Message from the Guest Editors

This Special Issue is titled “Novel Drugs for Treating Gynecologic Cancers”. Gynecologic cancer treatment has reached a major turning point thanks to the development of molecularly targeted agents and immune-checkpoint inhibitors. In particular, in ovarian cancer treatment, testing for *BRCA* and HRD status is expected to further improve prognosis by combining molecular targeted agents with different mechanisms of action. This Special Issue aims to collect original research studies and review articles (either systematic or discursive), clinical trials, and short communications adding to the current knowledge and showing potential future approaches of novel agents for gynecologic cancers.

Guest Editors

Prof. Dr. Tadahiro Shoji

Department of Obstetrics and Gynecology, Iwate Medical University, Yahaba, Japan

Prof. Dr. Hiroaki Itamochi

Department of Clinical Oncology, Iwate Medical University, Yahaba, Japan

Deadline for manuscript submissions

closed (5 January 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/145407

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)